MARINOMED BIOTECH AG

ISIN: ATMARINOMED6 WKN: - Asset Class: Stock



Company Profile

Marinomed Biotech AG is a biopharmaceutical company, which engages in the development of therapies based on patent protected technology platforms. It operates through the following segments: Immunology, Virology, and Other. The company was founded by Andreas Grassauer and Eva Prieschl-Grassauer in 2006 and is headquartered in Korneuburg, Austria.

Financial figures, Fiscal year: from 01.01. to 31.12.

| | 2023 | | 2022 | | 2021 | |
|--------------------------------|------------|------------------------|------------|------------------------|------------|------------------------|
| Financial figures | Assets | Liabilities and equity | Assets | Liabilities and equity | Assets | Liabilities and equity |
| Current assets | 7,135,000 | | 14,267,000 | | 12,877,000 | |
| Common stock capital | | 1,523,000 | | 1,506,000 | | 1,480,000 |
| Fixed assets | 7,476,000 | | 8,019,000 | | 8,459,000 | |
| Equity capital of a company | | -10,136,000 | | -4,157,000 | | 191,000 |
| Cash and cash equivalents | 2,588,000 | | 8,175,000 | | 5,802,000 | |
| Accrued liabilities | | 0 | | 0 | | 0 |
| Other assets | - | | - | | - | |
| Current liabilities | | 9,653,000 | | 5,956,000 | | 6,013,000 |
| Prepayments and accrued income | - | | - | | - | |
| Non-current liabilities | | 15,094,000 | | 20,487,000 | | 15,131,000 |
| Different income | | - | | - | | - |
| Other liabilities | | 254,000 | | 304,000 | | 87,000 |
| Total assets | 14,611,000 | 14,611,000 | 22,286,000 | 22,286,000 | 21,337,000 | 21,337,000 |

Balance notes

| | 2023 | 2022 | 2021 |
|---------------------|----------|----------|------------|
| Accounting standard | IFRS | IFRS | IFRS |
| Employees | 52 | 49 | 47 |
| Equity ratio | -69.37% | -18.65% | 0.90% |
| Debt-equity ratio | -244.15% | -636.11% | 11,047.86% |

Others

| | 2023 | 2022 | 2021 |
|------------------|--------|--------|--------|
| Tax Expense Rate | -0.06% | -0.11% | -3.46% |

MARINOMED BIOTECH AG

ISIN: ATMARINOMED6 WKN: - Asset Class: Stock

| Income statement | | | |
|--|------------|------------|------------|
| | 2023 | 2022 | 2021 |
| Turnover | 9,183,000 | 11,275,000 | 11,627,000 |
| Net income | -6,794,000 | -6,397,000 | -5,891,000 |
| EBIT | -4,317,800 | -3,882,900 | -4,185,100 |
| Operating income before taxes | -6,790,000 | -6,390,000 | -5,694,000 |
| Cash Flow | -4,528,000 | -5,202,000 | -4,866,000 |
| Net interest income | -2,473,000 | -2,508,000 | -1,509,000 |
| Research and development expenses | 7,032,000 | 6,905,000 | 7,504,000 |
| Income taxes | 4,000 | 6,000 | 197,000 |
| Result from investments in subsidaries, associates and other | 0 | 0 | 0 |
| Revenues per employee | 176,606 | 230,120 | 247,400 |

| Board of Directors | |
|---------------------------|-------------------------------|
| Simon Nebel | Chairman of Supervisory Board |
| Elisabeth Lackner | Member of Supervisory Board |
| Eva Hofstädter-Thalmann | Member of Supervisory Board |
| Brigitte Ederer | Member of Supervisory Board |
| Ulrich Kinzel | Member of Supervisory Board |

| Members of Management Board | | | |
|-------------------------------|---|--|--|
| Chairman of Managing Board | | | |
| Member of Executive Committee | | | |
| Member of Executive Committee | | | |
| | Chairman of Managing Board Member of Executive Committee | | |